Puma Biotechnology, Inc. PBYI
Puma Biotechnology, Inc. (Nasdaq: PBYI) is an oncology drug developer. Its lead program, NERLYNX (neratinib), is in Phase 2 for HER2-positive breast cancer (extended adjuvant and metastatic).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NERLYNX (neratinib) | HER2-positive breast cancer | small molecule | Approved |
| alisertib | extensive stage small cell lung cancer (ALISCA-Lung1) | small molecule | Phase 2 |
| alisertib | HR+/HER2- breast cancer (ALISCA-Breast1) | small molecule | Phase 2 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
- Faeth Therapeutics, Inc. FTH
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.